{"DataElement":{"publicId":"2554657","version":"1","preferredName":"Additional Treatment Progression Type","preferredDefinition":"the type of additional treatment that a patient receives following a diagnosis of progression or a change in protocol therapy.","longName":"ADD_TX_PROG_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2196244","version":"1","preferredName":"Additional Treatment Progression","preferredDefinition":"information related to the additional treatment for progression.","longName":"ADD_TX_PROG","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206682","version":"1","preferredName":"Additional Therapy","preferredDefinition":"Added; extra. (from American Heritage Dictionary):An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25406:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FFCA-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177380","version":"1","preferredName":"Progression","preferredDefinition":"Progression; advancement in extent or severity.","longName":"Progression","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Progression","conceptCode":"C25331","definition":"Progression; advancement in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-5267-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EE80BE2B-9BBB-0CFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2554658","version":"1","preferredName":"Additional Treatment Progression Type","preferredDefinition":"the type of additional treatment that a patient receives following a diagnosis of progression or a change in protocol therapy.","longName":"ADD_TX_PROG_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Anastrozole","valueDescription":"ANASTROZOLE","ValueMeaning":{"publicId":"2561407","version":"1","preferredName":"ANASTROZOLE","longName":"2561407","preferredDefinition":"ANASTROZOLE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCEC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"24A5CCA1-E134-6836-E044-0003BA3F9857","beginDate":"2006-12-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-15","modifiedBy":"ONEDATA","dateModified":"2006-12-15","deletedIndicator":"No"},{"value":"Exemestane","valueDescription":"Exemestane","ValueMeaning":{"publicId":"2563643","version":"1","preferredName":"Exemestane","longName":"2563643","preferredDefinition":"A synthetic androgen analogue.  Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exemestane","conceptCode":"C1097","definition":"An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C5A8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-05","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"24A5CCA1-E13F-6836-E044-0003BA3F9857","beginDate":"2006-12-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-15","modifiedBy":"ONEDATA","dateModified":"2006-12-15","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"TAMOXIFEN","ValueMeaning":{"publicId":"2561706","version":"1","preferredName":"TAMOXIFEN","longName":"2561706","preferredDefinition":"TAMOXIFEN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE17-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"24A5CCA1-E14A-6836-E044-0003BA3F9857","beginDate":"2006-12-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-15","modifiedBy":"ONEDATA","dateModified":"2006-12-15","deletedIndicator":"No"},{"value":"Fulvestrant","valueDescription":"Fulvestrant","ValueMeaning":{"publicId":"2575943","version":"1","preferredName":"Fulvestrant","longName":"2575943","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"24A5CCA1-E155-6836-E044-0003BA3F9857","beginDate":"2006-12-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-15","modifiedBy":"ONEDATA","dateModified":"2006-12-15","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"24A5CCA1-E160-6836-E044-0003BA3F9857","beginDate":"2006-12-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-15","modifiedBy":"ONEDATA","dateModified":"2006-12-15","deletedIndicator":"No"},{"value":"Letrozole","valueDescription":"LETROZOLE","ValueMeaning":{"publicId":"2561408","version":"1","preferredName":"LETROZOLE","longName":"2561408","preferredDefinition":"LETROZOLE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"27A54BE7-AD35-7339-E044-0003BA3F9857","beginDate":"2007-01-22","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-01-22","modifiedBy":"ONEDATA","dateModified":"2007-01-22","deletedIndicator":"No"},{"value":"Chemotherapy","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"2570169","version":"1","preferredName":"Chemotherapy","longName":"2570169","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DF26-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-9A6C-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Radiation Therapy","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2717922","version":"1","preferredName":"Radiation Therapy","longName":"2717922","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42BFA254-C33F-032A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-9A77-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Best supportive care, hospice","valueDescription":"Best supportive care, hospice","ValueMeaning":{"publicId":"3185012","version":"1","preferredName":"Best supportive care, hospice","longName":"3185012","preferredDefinition":"Best supportive care, hospice","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4A1E1E-9A03-CF75-E040-BB89AD433EF9","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-9A1C-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Non-surgical ablation of metastases","valueDescription":"Non-surgical ablation of metastases","ValueMeaning":{"publicId":"3185013","version":"1","preferredName":"Non-surgical ablation of metastases","longName":"3185013","preferredDefinition":"Non-surgical ablation of metastases","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4A1E1E-9A26-CF75-E040-BB89AD433EF9","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-9A3F-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Surgical resection of metastases","valueDescription":"Surgical resection of metastases","ValueMeaning":{"publicId":"3185014","version":"1","preferredName":"Surgical resection of metastases","longName":"3185014","preferredDefinition":"Surgical resection of metastases","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4A1E1E-9A49-CF75-E040-BB89AD433EF9","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4A1E1E-9A62-CF75-E040-BB89AD433EF9","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Surgical resection","valueDescription":"Surgical Resection","ValueMeaning":{"publicId":"3125096","version":"1","preferredName":"Surgical Resection","longName":"3125096","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.: Resected; having been removed by surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Resected","conceptCode":"C25654","definition":"Having been removed by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C919EDE-7C1A-087E-E040-BB89AD43596A","latestVersionIndicator":"Yes","beginDate":"2010-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A41B27D2-CEA2-569B-E040-BB89AD432493","beginDate":"2011-05-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-25","modifiedBy":"ONEDATA","dateModified":"2011-05-25","deletedIndicator":"No"},{"value":"Stereotactic radiosurgery","valueDescription":"Stereotactic Radiosurgery","ValueMeaning":{"publicId":"2578537","version":"1","preferredName":"Stereotactic Radiosurgery","longName":"2578537","preferredDefinition":"A type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. It is also being studied in the treatment of other types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stereotactic Radiosurgery","conceptCode":"C15358","definition":"A non-surgical procedure that was developed to deliver one or several maximum dose targeted radiation treatments for cancers in the brain or spine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFD6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-04-05","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A41B27D2-CEB6-569B-E040-BB89AD432493","beginDate":"2011-05-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-25","modifiedBy":"ONEDATA","dateModified":"2011-05-25","deletedIndicator":"No"},{"value":"Whole brain radiation therapy","valueDescription":"Whole-Brain Radiotherapy","ValueMeaning":{"publicId":"3238268","version":"1","preferredName":"Whole-Brain Radiotherapy","longName":"3238268","preferredDefinition":"Radiation treatment modality used as major component in treatment of primary and metastatic brain tumors. This is a standard treatment for multiple brain metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Whole-Brain Radiotherapy","conceptCode":"C16187","definition":"Radiation treatment modality used as major component in treatment of primary and metastatic brain tumors. This is a standard treatment for multiple brain metastases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41B27D2-CEC0-569B-E040-BB89AD432493","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A41B27D2-CED8-569B-E040-BB89AD432493","beginDate":"2011-05-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-25","modifiedBy":"ONEDATA","dateModified":"2011-05-25","deletedIndicator":"No"},{"value":"Patients randomized to Arm A (vinorelbine + placebo) - Crossover to open-label linsitinib","valueDescription":"Patients randomized to Arm A (vinorelbine + placebo) - Crossover to open-label linsitinib","ValueMeaning":{"publicId":"3342471","version":"1","preferredName":"Patients randomized to Arm A (vinorelbine + placebo) - Crossover to open-label linsitinib","longName":"3342471","preferredDefinition":"Patients randomized to Arm A (vinorelbine + placebo) - Crossover to open-label linsitinib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5A59CA8-73FA-DFFC-E040-BB89AD432892","latestVersionIndicator":"Yes","beginDate":"2012-01-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B5A59CA8-7413-DFFC-E040-BB89AD432892","beginDate":"2012-01-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-03","modifiedBy":"ONEDATA","dateModified":"2012-01-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"24A5BED7-F082-6F3D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-15","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient has crossed to the fo","type":"Preferred Question Text","description":"Patient has crossed to the following treatment","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Subsequent treatment type","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Unblinding and Treatment Instructions","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"24A5B786-6037-6F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-12-15","modifiedBy":"SHIDED","dateModified":"2012-01-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}